Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.

Imbruvica plus venetoclax significantly extends PFS in untreated CLL patients compared to chlorambucil plus Gazyva, with 52 months versus 31 months. The combination therapy shows durable efficacy and ...

People with Medicare Part D plans shoulder a share of the cost of their prescription drugs. Under the standard Part D benefit ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment of chronic lymphocytic leukaemia (CLL).

In the ELEVATE-RR study, Calquence (acalabrutinib) matched Imbruvica (ibrutinib) when it came to keeping adults with previously treated, high-risk CLL alive without disease progression at a median ...

Martin Dreyling, MD, discusses how the safety and efficacy results from the TRIANGLE study in mantle cell lymphoma differ from prior expectations.

Discover why JNJ's long-term buy rating is supported by its blue-chip status, profitability, and diverse revenue lines, ...